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Intraplaque Hemorrhage as a
Stimulator of Episodic Growth of Advanced,
But Nonsymptomatic Atherosclerotic Lesions
Bridging the Gap*
Mat J. Daemen, MD, PHD,† Marianne Eline Kooi, PHD‡
Maastricht, the NetherlandsBoth cross-sectional histological studies of human
atherosclerotic specimens and a plethora of studies
in animal models have provided the current frame-
work for the pathogenesis of atherosclerosis. One
major drawback of the current hypotheses is the
paucity of longitudinal observations in humans on
the natural history of atherosclerosis. Noninvasive
imaging studies of human atherosclerosis are able to
bridge the gap between cross-sectional pathology
observations, animal studies, and longitudinal ob-
servations in humans.
See page 1381
In this issue of iJACC, Underhill et al. (1)
followed for 18 months the development of athero-
sclerosis in the carotid artery of 67 nonsymptomatic
patients with 16% to 49% stenosis who were re-
ferred because of a cervical bruit or because they
were scheduled for coronary bypass graft or lower
extremity bypass. They identified intraplaque hem-
orrhage (IPH), systolic blood pressure, and statins
as the determinants of a change in plaque burden.
IPH as a source of intraplaque growth. Although only
12 (18%) of 67 patients showed evidence of IPH,
the presence of IPH was associated with a reduction
in lumen volume and an increase in plaque volume,
without outward remodeling of the vessel.
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
From the Departments of †Pathology and ‡Radiology, Cardiovascular
Research Institute Maastricht, Maastricht University Medical Center,
Maastricht, the Netherlands.The observations that only 18% of the subjects
had IPH and that no subjects developed IPH in the
18-month period are intriguing because they sug-
gest that IPH does not occur very often in non-
symptomatic carotid plaques, and if it does, it only
occurs in a subgroup of plaques and/or patients.
It also suggests that if IPH occurs, it has potent,
long-standing, and stimulatory effects on plaque
growth. This plaque growth stimulatory effect is
most likely due to the response of the plaque to the
presence of erythrocytes and possibly fibrin, which
will evoke a classic wound-healing response in the
plaque, resulting in the deposition of first loosely
oriented and later more mature and cross-linked
intraplaque collagens and the formation of new
intraplaque vessels. Indeed, cholesterol-rich eryth-
rocytes do attract macrophages into the plaque,
leading to phagocytosis of cholesterol-rich erythro-
cytes, hemoglobin release, and iron deposition. The
resulting highly reactive milieu in the plaque forms
the base for the wound-healing response and an
increase in plaque volume. Erythrocyte phagocyto-
sis does indeed occur in atherosclerotic plaques (2),
but is dysfunctional in advanced atherosclerosis and
may be limited in capacity.
The observations that IPH remained detectable
in the same plaque even after 18 months indicates
that either IPH does not resolve very rapidly or that
IPH recurs in the same plaque, as suggested by
Takaya et al. (3). Evaluation of the age and volume
of the IPH is essential to discriminate new from
existing IPH, but was not provided. The apparent
observation that IPH does not resolve rapidly or
does not resolve at all suggests that, in addition to
dysfunctional erythrocyte phagocytosis, a normal
thrombotic sequence does not occur or inadequately
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1391ccurs. One possibility is that plaques with IPH
ontain high amounts of thrombolytic factors,
hich may prevent thrombus formation. Molecular
maging is necessary to report on fibrin deposition
nd/or thrombus formation, which is indeed possi-
le, mainly in the pre-clinical phase (4,5).
Intraplaque microvessels, which originate from
he adventitia, are candidate entry sites of erythro-
ytes. Hypoxia-dependent and -independent mo-
ecular mechanisms of plaque microvessel formation
ave been identified (6). Recently, Sluimer et al. (7)
emonstrated evidence of leaky and dysfunctional
laque microvessels with altered endothelial–
ndothelial junctions and a low mural cell coverage.
ecause these intraplaque microvessels were spa-
ially linked to monocytes and erythrocytes, they
ay indeed function as entry sites of plaque con-
tituents and provide a novel source for intraplaque
nflammation and hemorrhage.
One important issue is whether the identification of
emorrhage on multisequence magnetic resonance
maging (MRI) does indeed reflect true IPH. Because
f obvious reasons, the findings in the present study
1) are not substantiated by histology. Several groups
ave presented data that show that the presence of
PH can be established with MRI (8–10). The
orrelation between volumetric measurements of
emorrhage on MRI and histology was reported to be
oderate to strong (9), whereas the age of IPH
annot be measured reproducibly (10). Although we
ave always thought that IPH was a feature of very
dvanced plaques (and thus involving symptomatic
atients), the findings in the present study (1) indicate
hat a substantial fraction of these asymptomatic
atients do show evidence of IPH. The data also
ndicate that IPH could represent an important accel-
rator of plaque growth, even at a stage at which an
dvanced plaque has developed but has not produced
linical symptoms. Note that although by definition
umen volume was still substantial in these asymptom-
tic patients, plaque volume was also substantial and
laques were advanced because 58% of the plaques
easured had a lipid-rich necrotic core, albeit with a
imited volume of 80 mm3, representing only 15% to
5% of the total plaque volume. Thus, the real novelty
f the findings is not that IPH does occur in advanced
esions and that its frequency increases with an in-
rease in stenosis (11), but that IPH does occur in
dvanced lesions of asymptomatic patients. Unfortu-
ately, other assumed key parameters of the risk of
laque rupture such as fibrous cap thickness and, as
iscussed earlier, the presence of a thrombus, were not
easured. tAssuming that IPH is a major driver of plaque
rowth (3), even in asymptomatic patients, the ques-
ion arises whether asymptomatic patients with ad-
anced lesions and specific features such as IPH need
o be treated because these lesions have a higher
hance to progress to symptomatic lesions and ulti-
ately to rupture. Therapeutic options are, however,
imited. Adequate statin treatment and blood pressure
ontrol are evident. Indeed, also in this study (1),
therosclerosis did not progress in the patients
reated with statins, whereas total wall volume
ncreased 22 mm3/year in the 24 patients who
ere not taking statins, which represents a rela-
ive increase of 3%. Hypertension was also asso-
iated with an increase in wall volume.
Whether plaque microvessels are a suitable target to
educe plaque growth and possible plaque inflamma-
ion is currently unknown. The recent findings that
hese plaque microvessels are rather immature (7)
uggests that stimulation of plaque microvessel
aturation might be a better target than a simple
eduction in the number of microvessels, which
ay increase the hypoxia in the plaque and
hereby increase the size of the necrotic core.
ow to progress? Although this study (1) does
eveal that IPH contributes to plaque progression,
ven in asymptomatic lesions, it does have limita-
ions. One limitation is the small sample size of
nly 67 patients, the majority of whom were sched-
led for either coronary or peripheral bypass graft-
ng, which may have introduced a selection bias. A
econd limitation is that the data were obtained and
nalyzed at 1 center and the follow-up time was
nly 18 months, which may seem long, but repre-
ents only a fraction of the lifetime of an athero-
clerotic lesion, which takes decades to mature.
ecause it was technically impossible to measure
he IPH volume, the IPH group was mixed, includ-
ng lesions with large and small IPH. In addition,
rowth or regression and location and age of the
PH were not evaluated. The lack of cholesterol
evels is a serious omission, and readers must be
ware that these measurements were performed in
he carotid artery, which may not yield the same
esults as the coronary artery.
However, now that we know that IPH (and
ossibly other key parameters of the risk of plaque
upture) is present in a subgroup of even asymp-
omatic patients and remains detectable for at least
8 months, we need to establish whether other key
arameters of the risk of rupture are also present in
hese lesions and whether this subset of plaques also
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1392ncreases the risk of the development of a stroke, as
as recently suggested by Altaf et al. (12).
Indeed, noninvasive imaging of at least the ca-
otid artery and in the near future possibly also of
he coronary artery (13) starts to bridge the gap
etween our concepts based on cross-sectional his-
ological observations and the real natural history of
n atherosclerotic plaque. This opens the possibilityalpha2-antiplasmin-based contrast 2005;25:234–9.ndividual atherosclerotic plaque, even when it is
till asymptomatic.
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